Study of BAT4406F injection for MCD and FSGS
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an injected drug called BAT4406F for people with Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS), two types of kidney diseases that cause swelling and high protein in urine. It aims to see if the drug can help patients who have responded well to steroid therapy in the past.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Minimal Change Disease or Focal Segmental Glomerulosclerosis through a kidney biopsy within the last 7 years (for MCD) or 10 years (for FSGS).
- Your kidney disease has been active or come back recently, and you achieved complete remission with steroids within the last 8 weeks.
- You have not had any treatments that target B-cells (like rituximab) in the last 6 months.
- You have not taken other immune-suppressing drugs (like cyclophosphamide) in the last 60 days.
- You do not have active infections like hepatitis B, hepatitis C, syphilis, or HIV.
- You do not have a known allergy to monoclonal antibodies or a strong history of allergies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
This trial tests if obinutuzumab, a targeted therapy, can safely and effectively treat adults with their first episode of minimal change disease (MCD), a kidney condition causing protein leakage. Participants will receive the drug to see if it reduces protein in urine and improves symptoms.
This study collects medical information and samples from patients with podocytopathy—a type of autoimmune kidney disease that causes protein leakage into urine. Researchers will analyze your medical records and any blood or kidney tissue samples you've already had to better understand the disease and find better treatments.
This trial tests a combination of four medications (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with monoclonal immunoglobulin deposition disease (MIDD), a condition where abnormal proteins build up in organs. The goal is to see if this treatment can help without prior harsh therapies.
This trial tests a new drug called B007 for people with primary membranous nephropathy, a kidney condition. It aims to see if B007 can help reduce protein in the urine and protect kidney function.
Hear when a new Focal Segmental Glomerulosclerosis (FSGS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.